Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?

References

• WHO. WHO Classification of Head and Neck Tumours - 4th Edition. El-Naggar AK, Chan JKC, Grandis JR, et al., ed.. 2017.
   Google Scholar
• Laurie SA, Licitra, L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24(17):2673–2678.
   PubMed Web of Science ®Google Scholar
• Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45(7):791–798.
   PubMed Web of Science ®Google Scholar
• Ross, JS, Wang K, Rand JV, et al. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. Am J Surg Pathol. 2014;38(2):235–238.
   PubMed Web of Science ®Google Scholar
• Yin LX, Ha PK. Genetic alterations in salivary gland cancers. Cancer. 2016;122(12):1822–1831.
   PubMed Web of Science ®Google Scholar
• Grunewald I, Vollbrecht C, Meinrath J, et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget. 2015;6(20):18224–18237.
   PubMedGoogle Scholar
• Kato S, Elkin SK, Schwaederle M, et al. Genomic landscape of salivary gland tumors. Oncotarget. 2015;6(28):25631–25645.
   PubMedGoogle Scholar
• Ross JS, Gay LM, Wang K, et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol. 2017;28(10):2539–2546.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MIW, Borresen-Dale, AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157–2165.
   PubMed Web of Science ®Google Scholar
• Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol. 2009;45(11):986–990.
   PubMed Web of Science ®Google Scholar
• Mitani Y, Rao PH, Maity SN, et al. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014;20(24):6570–6581.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Sharma A, Schmitt NC, et al. A 20-year review of 75 cases of salivary Duct Carcinoma. JAMA Otolaryngol Head Neck Surg. 2016;142(5):489–495.
   PubMed Web of Science ®Google Scholar
• Dalin MG, Watson P, Ho A, et al. Androgen receptor signaling in salivary gland cancer. Cancers (Basel). 2017;9(2):pii: E17.
   PubMed Web of Science ®Google Scholar
• Locati LD, Perrone F, Cortelazzi B, et al. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck. 2016;38(5):724–731.
   PubMed Web of Science ®Google Scholar
• Dalin, MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res. 2016;22(18):4623–4633.
   PubMed Web of Science ®Google Scholar
• Alfieri S, Granata R, Bergamini C, et al. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. Oral Oncol. 2017;66:58–63.
   PubMed Web of Science ®Google Scholar
• Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29(4):979–984.
   PubMed Web of Science ®Google Scholar
• Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck. 2018;40(3):605–613.
   PubMed Web of Science ®Google Scholar
• Locati LD, Perrone F, Cortelazzi B, et al. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther. 2014;15(6):678–682.
   PubMed Web of Science ®Google Scholar
• Enzalutamide for patients with androgen receptor positive salivary cancers - NCT02749903. cited 2018 Dec 07]; Available from: https://clinicaltrials.gov/ct2/show/NCT02749903.
   Google Scholar
• Cappelletti V, Miodini P, Reduzzi C, et al. Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: aRv7 expression in circulating tumor cells. Ann Oncol. 2018;29(7):1598–1600.
   Web of Science ®Google Scholar
• Udager AM, Chiosea SI. Salivary duct carcinoma: an update on morphologic mimics and diagnostic use of androgen receptor immunohistochemistry. Head Neck Pathol. 2017;11(3):288–294.
   PubMed Web of Science ®Google Scholar
• Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009;45(7):574–578.
   PubMed Web of Science ®Google Scholar
• Jakob JA, Kies MS, Glisson BS, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37(5):644–649.
   PubMed Web of Science ®Google Scholar
• Cros J, Sbidian E, Hans S, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol. 2013;24(10):2624–2629.
   PubMed Web of Science ®Google Scholar
• Dagrada GP, Negri T, Tamborini E, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology. 2004;44(3):301–302.
   PubMed Web of Science ®Google Scholar
• Clauditz TS, Reiff M, Gravert L, et al. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. Pathology. 2011;43(5):459–464.
   PubMed Web of Science ®Google Scholar
• Ettl T, Baader K, Stiegler C, et al. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer. 2012;106(4):719–726.
   PubMed Web of Science ®Google Scholar
• Ettl T, Stiegler C, Zeitler K, et al. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol. 2012;43(6):921–931.
   PubMed Web of Science ®Google Scholar
• Andreasen S, Grauslund M, Heegaard S. Lacrimal gland ductal carcinomas: clinical, Morphological and Genetic characterization and implications for targeted treatment. Acta Ophthalmol. 2017;95(3):299–306.
   PubMed Web of Science ®Google Scholar
• Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39(7):724–727.
   PubMed Web of Science ®Google Scholar
• Limaye SA, Posner MR, Krane JF, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18(3):294–300.
   PubMed Web of Science ®Google Scholar
• Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25(25):3978–3984.
   PubMed Web of Science ®Google Scholar
• My Pathway: A Study Evaluating Herceptin/ Perjeta,Tarceva, Zelboraf/ Cotellic,Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - NCT02091141.
   Google Scholar
• van Boxtel W, Boon E, Weijs WLJ, et al. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. Oral Oncol. 2017;72:198–200.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tada Y, Saotome T, et al. Phase II Trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37(2):125-134.
   Web of Science ®Google Scholar
• Can NT, Lingen MW, Mashek H, et al. Expression of hormone receptors and HER-2 in benign and malignant salivary gland tumors. Head Neck Pathol. 2018;12(1):95–104.
   PubMed Web of Science ®Google Scholar
• Wang K, Russell JS, McDermott JD, et al. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clin Cancer Res. 2016;22(24):6061–6068.
   PubMed Web of Science ®Google Scholar
• Wang K, McDermott JD, Schrock AB, et al. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol. 2017;28(4):748–753.
   PubMed Web of Science ®Google Scholar
• Clauditz TS, Gontarewicz A, Bokemeyer C, et al. Abundant expression of mTOR kinase in salivary gland tumors - potentials as therapy target?. J Oral Pathol Med. 2013;42(10):769–773.
   PubMed Web of Science ®Google Scholar
• Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34(5):599–608.
   PubMed Web of Science ®Google Scholar
• Skalova A, Vanecek T, Martinek P, et al. Molecular Profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 Cases. Am J Surg Pathol. 2018;42(2):234–246.
   PubMed Web of Science ®Google Scholar
• Andreasen S, Skálová A, Agaimy A, et al. ETV6 Gene Rearrangements characterize a morphologically distinct subset of sinonasal low-grade non-intestinal-type adenocarcinoma: a novel translocation-associated carcinoma restricted to the sinonasal tract. Am J Surg Pathol. 2017;41(11):1552–1560.
   PubMed Web of Science ®Google Scholar
• Andreasen S, Kiss K, Melchior LC, et al. The ETV6-RET gene fusion is found in ETV6-rearranged low-grade sinonasal adenocarcinoma without NTRK3 involvement. Am J Surg Pathol. 2018;42(7):985–988.
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392–3408.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27(5):920–926.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Paz-Ares L, Farago AF, LBA17 – Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive (NTRK-fp) Tumors: Pooled Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. 2018.
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Porta R, Borea R, Coelho A, et al. FGFR a promising druggable target in cancer: molecular biology and new drugs. Crit Rev Oncol Hematol. 2017;113:256–267.
   PubMed Web of Science ®Google Scholar
• Ach T, Schwarz‐Furlan S, Ach S, et al. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. J Oral Pathol Med. 2016;45(7):500–509.
   PubMed Web of Science ®Google Scholar
• Dalin MG, Katabi N, Persson M, et al. Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat Commun. 2017;8(1):1197.
   PubMed Web of Science ®Google Scholar
• Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
   PubMed Web of Science ®Google Scholar
• Martens-de Kemp SR, Brink A, van der Meulen, IH, et al. The FA/BRCA pathway identified as the major predictor of cisplatin response in head and neck cancer by functional genomics. Mol Cancer Ther. 2017;16(3):540–550.
   PubMed Web of Science ®Google Scholar
• Nardi V, Sadow PM, Juric D, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013;19(2):480–490.
   PubMed Web of Science ®Google Scholar
• Ho AL. Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. Ann Oncol. 2018;29(suppl 8):viii372–viii399.
   Google Scholar
• Choudhry Z, Rikani AA, Choudhry AM, et al. Sonic hedgehog signalling pathway: a complex network. Ann Neurosci. 2014;21(1):28–31.
   PubMedGoogle Scholar
• Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2010;2(4):237–250.
   PubMedGoogle Scholar
• Vidal MT, Lourenço SV, Soares FA, et al. The sonic hedgehog signaling pathway contributes to the development of salivary gland neoplasms regardless of perineural infiltration. Tumour Biol. 2016;37(7):9587–9601.
   PubMedGoogle Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–1909.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Facchinetti F, Haspinger, ER, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2014;89(2):284–299.
   PubMed Web of Science ®Google Scholar
• Ma PC, Tretiakova, MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008;47(12):1025–1037.
   PubMed Web of Science ®Google Scholar
• Garcia-Vilas JA, Medina MA. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications. World J Gastroenterol. 2018;24(33):3695–3708.
   PubMed Web of Science ®Google Scholar
• Ach T, Zeitler K, Schwarz-Furlan S, et al. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch. 2013;462(1):65–72.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608.
   PubMed Web of Science ®Google Scholar
• Goto Y. Tumor mutation burden: is it ready for the clinic? J Clin Oncol. 2018;;36(30):2978-2979.
   Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Mukaigawa T, Hayashi R, Hashimoto K, et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol. 2016;114(1):36–43.
   PubMed Web of Science ®Google Scholar
• Cohen RB. Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. J Clin Oncol. 2016;34(suppl):6017.
   Web of Science ®Google Scholar
• Nivolumab in recurrent or metastatic salivary gland carcinoma of the head and neck (NISCAHN) - NCT03132038. 2018 Dec 07]; Available from: https://clinicaltrials.gov/ct2/show/NCT03132038.
   Google Scholar
• Nivolumab and Ipilimumab in treating patients with metastatic/recurrent ACC of all sites and non-acc salivary gland cancer - NCT03146650. cited 2018 Dec 07]; Available from: https://clinicaltrials.gov/ct2/show/NCT03146650.
   Google Scholar
• Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013;7(Suppl 1):S12–9.
   PubMedGoogle Scholar
• Weinreb I. Translocation-associated salivary gland tumors: a review and update. Adv Anat Pathol. 2013;20(6):367–377.
   PubMed Web of Science ®Google Scholar
• Tirado Y, Williams MD, Hanna EY, et al. CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin‘s tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer. 2007;46(7):708–715.
   PubMed Web of Science ®Google Scholar
• Kang H, Tan M, Bishop JA, et al. Whole-exome sequencing of salivary gland mucoepidermoid carcinoma. Clin Cancer Res. 2017;23(1):283–288.
   PubMed Web of Science ®Google Scholar
• Nakano T, Yamamoto H, Nishijima T, et al. Hyalinizing clear cell carcinoma with EWSR1-ATF1 fusion gene: report of three cases with molecular analyses. Virchows Arch. 2015;466(1):37–43.
   PubMed Web of Science ®Google Scholar
• Andreasen S, Varma S, Barasch N, et al. The HTN3-MSANTD3 fusion gene defines a subset of acinic cell carcinoma of the salivary gland. Am J Surg Pathol. 2019;43(4):489-496.
   Google Scholar
• Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869–1876.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Gainor JF, Rahal R, et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 2018;8(7):836–849.
   PubMed Web of Science ®Google Scholar
• Cabozantinib in advanced salivary gland cancer patients (Cabo ASAP) - NCT03729297. cited 2018 Dec 07]; Available from: https://clinicaltrials.gov/ct2/show/NCT03729297.
   Google Scholar
• FDA approves larotrectinib for solid tumors with NTRK gene fusions. [cited 2018 Dec 07]; Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626720.htm.
   Google Scholar
• Frezza AM, Trama A, Blay JY, et al. Networking in rare cancers: what was done, what‘s next. Eur J Surg Oncol. 2019;45(1):16-18.
   Google Scholar